Elekta AB (publ)
STO:EKTA B

Watchlist Manager
Elekta AB (publ) Logo
Elekta AB (publ)
STO:EKTA B
Watchlist
Price: 60.85 SEK 0.66% Market Closed
Market Cap: 23.2B SEK
Have any thoughts about
Elekta AB (publ)?
Write Note

Elekta AB (publ)
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Elekta AB (publ)
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Elekta AB (publ)
STO:EKTA B
Other Operating Expenses
-kr102m
CAGR 3-Years
-6%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
S
Surgical Science Sweden AB
STO:SUS
Other Operating Expenses
-kr14.3m
CAGR 3-Years
-68%
CAGR 5-Years
-99%
CAGR 10-Years
N/A
CellaVision AB
STO:CEVI
Other Operating Expenses
kr1k
CAGR 3-Years
N/A
CAGR 5-Years
0%
CAGR 10-Years
N/A
Getinge AB
STO:GETI B
Other Operating Expenses
kr525m
CAGR 3-Years
112%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arjo AB (publ)
STO:ARJO B
Other Operating Expenses
kr6m
CAGR 3-Years
N/A
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Sedana Medical AB (publ)
STO:SEDANA
Other Operating Expenses
-kr1.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Elekta AB (publ)
Glance View

Market Cap
23.2B SEK
Industry
Health Care

Elekta AB emanates sophistication and precision, standing at the forefront of medical technology. Established in 1972 by Lars Leksell, the Swedish innovator manifests a legacy deeply rooted in advancing oncology and neurosurgery treatment solutions. Elekta's forte lies in crafting state-of-the-art equipment and software that assist medical practitioners in treating complex cancers and brain disorders. Their products, such as the Leksell Gamma Knife and various advanced linear accelerators, showcase their commitment to minimally invasive treatment. By developing cutting-edge systems that refine radiation therapy and radio-surgery, Elekta plays a pivotal role in enhancing patient outcomes, offering more precise targeting of tumors with minimal damage to surrounding healthy tissues. Financially, Elekta thrives through a multi-faceted revenue model that harmoniously blends hardware sales with recurring income from maintenance services, software upgrades, and training. Their business strategy capitalizes on long-term relationships with healthcare providers, ensuring a steady demand for both product innovation and servicing their existing installations. By anchoring its revenue stream in this hybrid fashion, Elekta offers a compelling proposition for shareholders—a blend of resilient cash flow dynamics and growth through groundbreaking technological advancements. As the global healthcare landscape evolves, Elekta's continuous investment in research and development ensures they remain a venerated leader in tackling the world's challenges in cancer care and neurological disorders.

EKTA B Intrinsic Value
96.75 SEK
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Elekta AB (publ)'s Other Operating Expenses?
Other Operating Expenses
-102m SEK

Based on the financial report for Apr 30, 2024, Elekta AB (publ)'s Other Operating Expenses amounts to -102m SEK.

What is Elekta AB (publ)'s Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
-17%

Over the last year, the Other Operating Expenses growth was -57%. The average annual Other Operating Expenses growth rates for Elekta AB (publ) have been -6% over the past three years , -17% over the past five years .

Back to Top